Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  pan-HER/VEGFR2 receptor tyrosine kinase inhibitor BMS-690514
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-8 of 8 for your search:
Start Over
A Comparison Between BMS-690514 and Erlotinib in Patients Who Were Previously Treated for NSCLC
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA187-017, EUDRACT #: 2008-004691-44, NCT00743938
Efficacy and Safety of BMS-690514 in Combination With Letrozole to Treat Metastatic Breast Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA187-016, 2009-016622-13, NCT01068704
Trial of BMS-690514 in Non-Small Cell Lung Cancer Subjects Who Have Been Treated With Gefitinib or Erlotinib and Are Genotypically EGFR Mutation Positive or Who Have Had a Prior Response
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA187-020, NCT01167244
A Phase I Study of BMS-690514 in Patients With Advanced or Metastatic Solid Tumors
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA187-002, NCT00329004
A Phase I Study of BMS-690514 in Combination With Paclitaxel and Carboplatin
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA187-004, NCT00420186
Combination Trial of BMS-690514 in Combination With FOLFIRI and FOLFOX
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 to 65
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA187-005, NCT00479583
Phase I Study of BMS-690514 in Japanese Patients With Solid Tumors
Phase: Phase I
Type: Treatment
Status: Completed
Age: 20 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA187-006, NCT00516451
Pharmacokinetics and Metabolism of Radiolabeled BMS-690514 in Healthy Male Subjects
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 to 45
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA187-003, NCT00578916
Start Over